FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR

FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR

The present invention relates to a formulation optimized for a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor. Specifically, the present invention relates to an aqueous pharmaceutical formulation comprising a fusion protein dimer comprising an extra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jang, Myung Ho, Kwon, Soontak, Cho, Young-Gyu
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Jang, Myung Ho
Kwon, Soontak
Cho, Young-Gyu
description The present invention relates to a formulation optimized for a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor. Specifically, the present invention relates to an aqueous pharmaceutical formulation comprising a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor, histidine, proline, methionine, and poloxamer 188, wherein the pH of the formulation is from 6.0 to 7.0. The fusion protein present in the formulation according to the present invention is included at a high concentration, has improved stability, may be conveniently administered by subcutaneous injection, and has excellent IgE binding ability compared to a conventional therapeutic agent comprising an anti-IgE antibody. Thus, it can be usefully utilized as an injection for the treatment of allergic diseases mediated by IgE.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2024148829A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2024148829A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2024148829A13</originalsourceid><addsrcrecordid>eNqNi70KwjAURrM4iPoOF5wFGzvUMaY37YU0CfkBt1okTqKF-v5oxQdw-g6H8y3ZRVnfJS0iWQNWgUphJudtRDJARupUk2kAz9ELiVp_Yg-17QR9D0K7VkBIp2QozoIaBCXBo0QXrV-zxW24T3nz2xXbKoyy3eXx2edpHK75kV99CnzPy6KsKn4UxeG_6g1kOjRu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR</title><source>esp@cenet</source><creator>Jang, Myung Ho ; Kwon, Soontak ; Cho, Young-Gyu</creator><creatorcontrib>Jang, Myung Ho ; Kwon, Soontak ; Cho, Young-Gyu</creatorcontrib><description>The present invention relates to a formulation optimized for a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor. Specifically, the present invention relates to an aqueous pharmaceutical formulation comprising a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor, histidine, proline, methionine, and poloxamer 188, wherein the pH of the formulation is from 6.0 to 7.0. The fusion protein present in the formulation according to the present invention is included at a high concentration, has improved stability, may be conveniently administered by subcutaneous injection, and has excellent IgE binding ability compared to a conventional therapeutic agent comprising an anti-IgE antibody. Thus, it can be usefully utilized as an injection for the treatment of allergic diseases mediated by IgE.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240509&amp;DB=EPODOC&amp;CC=US&amp;NR=2024148829A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240509&amp;DB=EPODOC&amp;CC=US&amp;NR=2024148829A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Jang, Myung Ho</creatorcontrib><creatorcontrib>Kwon, Soontak</creatorcontrib><creatorcontrib>Cho, Young-Gyu</creatorcontrib><title>FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR</title><description>The present invention relates to a formulation optimized for a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor. Specifically, the present invention relates to an aqueous pharmaceutical formulation comprising a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor, histidine, proline, methionine, and poloxamer 188, wherein the pH of the formulation is from 6.0 to 7.0. The fusion protein present in the formulation according to the present invention is included at a high concentration, has improved stability, may be conveniently administered by subcutaneous injection, and has excellent IgE binding ability compared to a conventional therapeutic agent comprising an anti-IgE antibody. Thus, it can be usefully utilized as an injection for the treatment of allergic diseases mediated by IgE.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi70KwjAURrM4iPoOF5wFGzvUMaY37YU0CfkBt1okTqKF-v5oxQdw-g6H8y3ZRVnfJS0iWQNWgUphJudtRDJARupUk2kAz9ELiVp_Yg-17QR9D0K7VkBIp2QozoIaBCXBo0QXrV-zxW24T3nz2xXbKoyy3eXx2edpHK75kV99CnzPy6KsKn4UxeG_6g1kOjRu</recordid><startdate>20240509</startdate><enddate>20240509</enddate><creator>Jang, Myung Ho</creator><creator>Kwon, Soontak</creator><creator>Cho, Young-Gyu</creator><scope>EVB</scope></search><sort><creationdate>20240509</creationdate><title>FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR</title><author>Jang, Myung Ho ; Kwon, Soontak ; Cho, Young-Gyu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2024148829A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Jang, Myung Ho</creatorcontrib><creatorcontrib>Kwon, Soontak</creatorcontrib><creatorcontrib>Cho, Young-Gyu</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Jang, Myung Ho</au><au>Kwon, Soontak</au><au>Cho, Young-Gyu</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR</title><date>2024-05-09</date><risdate>2024</risdate><abstract>The present invention relates to a formulation optimized for a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor. Specifically, the present invention relates to an aqueous pharmaceutical formulation comprising a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor, histidine, proline, methionine, and poloxamer 188, wherein the pH of the formulation is from 6.0 to 7.0. The fusion protein present in the formulation according to the present invention is included at a high concentration, has improved stability, may be conveniently administered by subcutaneous injection, and has excellent IgE binding ability compared to a conventional therapeutic agent comprising an anti-IgE antibody. Thus, it can be usefully utilized as an injection for the treatment of allergic diseases mediated by IgE.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2024148829A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A38%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Jang,%20Myung%20Ho&rft.date=2024-05-09&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2024148829A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true